Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Portfolio
Technologies
Licensing Opportunities

Latest News

Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458

Read More

Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes

Read More

Ligand to Report Second Quarter Financial Results on July 29, 2021

Read More

Recent Events

Stock Snapshot

LGND
Nasdaq
Volume
Market Cap
Day Range
52-Week Range